Luis H. Camacho - Researcher Profile

Publications

2 shown

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer , Scott S. Tykodi , Laura Q.M. Chow +23 more

Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks...

2012 New England Journal of Medicine 7854 citations

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Antoni Ribas , Luis H. Camacho , Gabriel López-Berestein +10 more

Purpose Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance le...

2005 Journal of Clinical Oncology 583 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 8,437
Institution: St. Luke's Episcopal Hospital

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-1856-8641

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.